Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. is listed today as Esperion Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Esperion Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration Revenue $243.60 million (60%), Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received $148.80 million (37%).
Annual report (SEC XBRL) · Dec 2025
Esperion Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2013).
SEC Form D · Apr 2013
The industry group it chose in its notices: Other Health Care.
SEC Form D · Apr 2013
Products and services#
No products or services of Esperion Therapeutics, Inc. are on record.
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Aisling Capital II LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Aisling Capital Partners LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Aisling Capital Partners, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Alta Partners Management VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Alta Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Domain Parters VII L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| DP VII Associates LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Longitude Capital Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Longitude Capital Partners, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Longitude Venture Partners L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Louis G. Lange | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2013) | SEC Form 3 |
| Roger S. Newton | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2013) | SEC Form 3 |
Largest shareholders today
Institutions holding Esperion Therapeutics, Inc. shares, as of Sep 30, 2026.
- Asset Planning,Inc$0 M—
- Glenmede Trust Co NA$0 M—
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Noah L. Rosenberg | Executive officer | Apr 2013 |
| Roger S. Newton | Executive officer | Apr 2013 |
| Tim M. Mayleben | Executive officer | Apr 2013 |
| Troy A. Ignelzi | Executive officer | Apr 2013 |
| Daniel A. Janney | Director | Apr 2013 |
| Dov A. Goldstein | Director | Apr 2013 |
| Louis G. Lange | Director | Apr 2013 |
| Nicole G. Vitullo | Director | Apr 2013 |
| Patrick G. Enright | Director | Apr 2013 |
| Roger S. Newton | Director | Apr 2013 |
| Tim M. Mayleben | Director | Apr 2013 |
| Alison S. Kiley | Director | Feb 2011 |
| Dov S. Goldstein | Director | Feb 2011 |
| Louis M. Lange | Director | Feb 2011 |
| Nicole S. Vitullo | Director | Feb 2011 |
| Timothy M. Mayleben | Director | Feb 2011 |
| Alison S. de Bord | Director | Feb 2010 |
About
American pharmaceutical company.